Search results
Results from the WOW.Com Content Network
On Thursday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported third-quarter adjusted EPS of $12.46, up 8% year-over-year, beating the consensus of $11.69. The company reported sales of $3.72 ...
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending ...
Yahoo Finance Live examines Regeneron Pharmaceuticals' stock following reports of positive results in its eye treatment drug trials.
Regeneron reported an adjusted profit of $11.56 per share on total revenue of $3.55 billion for the quarter, above analysts' estimates of $10.61 per share and $3.38 billion, according to LSEG data.
For premium support please call: 800-290-4726 more ways to reach us
Regeneron (REGN) closed at $615.88 in the latest trading session, marking a -0.8% move from the prior day. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...
For premium support please call: 800-290-4726 more ways to reach us